Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Global Pharmaceuticals & Biotechnology Royalty Rates Report 2022 with Theory Associated with Deriving Royalty Rates

Research and Markets Logo

News provided by

Research and Markets

May 23, 2022, 08:15 ET

Share this article

Share toX

Share this article

Share toX

DUBLIN, May 23, 2022 /PRNewswire/ -- The "Royalty Rates for Pharmaceuticals & Biotechnology, 9th Edition" report has been added to ResearchAndMarkets.com's offering.

Royalty Rates for Pharmaceuticals & Biotechnology features more real-deal royalty rates, license fees, and milestone payment benchmarks than any other publication.

The ninth edition of Royalty Rates for Pharmaceuticals & Biotechnology contains hundreds of royalty rates and other financial compensation benchmarks that can be used to optimize the pricing of biotechnology and pharmaceutical innovations. You'll find updated and expanded information from past editions as well as an increased number of reported license agreements.

This new edition and the transaction details have been collected from well-established sources over a period of 22 years of research. Royalty Rates for Pharmaceuticals & Biotechnology provides real-deal information for hundreds of transactions, including the technology licensed, royalty rates, license fees, and milestone payments. And it goes well beyond the rates to provide context for each deal analyzed.

This unique resource is organized into two useful sections:

The first section covers the theory associated with deriving royalty rates.

An overview of intellectual property value is included along with seven methods that can be employed to derive royalty rates: Simple Rules of Thumb, Industry Guidelines, Discounted Cash Flow Analysis, Risk-Adjusted Net Present Value Analysis, Infringement Damages Analysis, Comparable License Transactions, Investment Rate of Return Analysis, and the Relief-From-Royalty Method.

The second section of this one-of-a-kind report presents detailed financial information from real-world transactions. 

You'll find information on the parties involved in the transactions along with a description of the technology exchanged and all financial details that could be discovered. This publication is designed to provide accurate and authoritative information about the subject matter covered. 

Key Topics Covered:

  • 1,2-diphenylethanes, 1,3-diphenylpropanes and benzyl tetralins
  • Abuse Deterrent
  • Actimmune - interferon gamma-1b
  • Adult Growth Hormone Deficiency
  • Agriculture 
  • Alcohol Dependency Treatment
  • Aldurazyme - recombinant form of the human enzyme alpha-L-iduronidase
  • Alpha Interferon - Natural
  • Alzheimer's Treatment
  • Alzheimer's Diagnostic Test
  • Anemia
  • Anesthetic
  • Animal Health Products
  • Antibiotic
  • Antibodies
  • Antifungal
  • Antifungal Agent - Amphotericin B
  • Anti-hypertension Therapy
  • Arginine Products
  • Arthritis - Rheumatoid - Drug Humira
  • Asthma Drug - Oral Administration
  • Attention Deficit Hyperactivity Disorder
  • Attention Deficit Hyperactivity Disorder Therapy
  • Autoimmune Disease Therapy
  • Automated Cell Processing Instrument
  • Automated Process Research
  • Bacterial Infections
  • BetaKine (TGF-beta-2)
  • Bicifadine
  • Biochemical Technology Portfolio
  • Blood
  • BPI - Human Protein
  • Cancer
  • Cancer Diagnostics
  • Cancer- Histone Deacetylase (HDAC) Inhibitors
  • Cancer LukemiaTreatment
  • Cancer Research Technology
  • Cancer Therapy
  • Cancer Treatment
  • Cannabinoid Receptor Meditating Compounds
  • Cardiorenal Disease Therapies
  • Cardiovascular
  • Cartilage Regenerative Technology
  • Catheter Technology
  • cdkl Assay
  • Cell Adhesion Technology - LEC-CAM
  • Cell Cultures
  • Chimeric IgG1 antibodies
  • Cholesterol High LDL Treatment
  • Cholesterol Treatment
  • Chromosome Analysis Technology
  • Chronic Obstructive Pulmonary Disease Therapy
  • Cochleates, Liposomes and Proteoliposomes
  • Cold Remedy
  • Collagenase Ointment
  • Consensus Interferon
  • Contraceptive
  • Contrast Agent - Intravenous
  • COPD Treatment
  • Coronary Drug-eluting Stent
  • Cough Medicine
  • Crohn's Disease Therapy
  • Cyclin Dependent Kinasc Assay Test Kit
  • Cypress Stem Cells
  • Cystic Fibrosis Treatment
  • Cytomegalovirus Intravenous Treatment
  • Deferrum deferiprone
  • Dermatology
  • Diabetes
  • Diagnostic Alliance
  • Diagnostic Imagining Using Ligands
  • Dietary Supplement - Botanical
  • Diltiazem Heart Drug
  • DNA - PK
  • DNA Binding Invention
  • DNA Nanocircles
  • DNA Synthesis
  • Drug Delivery
  • EGF Fusion Protein
  • Eli Lilly & Co. Experiences Compulsory License Royalty Rates
  • Enoxaparin
  • Environmental Test Kit
  • Enzyme Inhibitors
  • Epilepsy Treatment - ADCI
  • EPO, Hepatitis B and IL-2
  • Erectial Dsyfuction Therapy - VitarosT
  • Erythronmycin Antibiotic
  • Estrogen Replacement Therapy
  • Fertility Treatment
  • Fibrotic Disease Therapy - Pirfenidone
  • Financing Research
  • Fusion Inihibitors for HIV
  • Gastrointestinal Infection
  • Gastroretentive Drug Delivery Devices for Oral Intake
  • Gene Activation Technology
  • Gene Alteration Technology
  • Gene Sequencing
  • Gene Splicing Technology
  • Gene Therapy Partnership Network
  • Genetic Abnormalities Test - Prenatal
  • Genetic Research
  • Genetic Technology
  • Genetically Engineered Listeria Immune Therapy
  • Genomics-based Drug Discovery
  • Glycogen Storage Disease III
  • Hepatitis
  • Hereditary Angioedema
  • Hereditary ATTR (hATTR) amyloidosis.
  • HIV and AIDS
  • Human Gene Technology
  • Human Growth Hormone
  • Human Monoclonal Antibodies Discovery Technology
  • Human Monoclonal Antibodu - Adalimumab
  • Humanization Antibody
  • Humanized Antibody
  • Humanized Monoclonal Antibody
  • Hypertension Treatment- autologous gene therapy
  • Hypertension Treatment- tadalafil
  • Immune (idiopathic) Thrombocytopenic Purpura Therapy
  • Immune System Enhancement
  • Immune System Regulators - Cytokines
  • Immunodeficiency
  • Immunotoxin - MDX-RA
  • Indiplon
  • Infections - Bacterial
  • Infertility Treatment - Male
  • Inflammation Antibody-based Therapeutics
  • Inflammatory - Topical Therapy
  • Inflammatory Diseases
  • Influenza Drug
  • Inhaler Technology
  • Insomnia
  • Insomnia Therapy
  • Integrelin Drug
  • Interferon Gamma-1b
  • Intracellular Receptor Technology
  • Kidney Disease Treatment
  • Liver Disease Therapy
  • Living Cells Connective Tissue
  • Lubrin
  • Lung Problems (Emphysema) Treatment
  • Lupis Nephritis
  • Lupus Nephritis
  • Macular Degeneration Therapy
  • Macular Therapy - Spinal Muscular Atrophy
  • Mammary Cell Growth Inhibitor
  • Metabolic Treatment
  • Michellamine B/Tropical Vine Leaves
  • Microorganism Detection in Water
  • Microsponge Delivery System
  • Migraine Relief
  • Modulation of Opioid Receptors
  • Monoclonal Antibodies Binding to TGF-B
  • Monoclonal Antibodies to Gram Negative Sepsis-Related Bacteria
  • Monoclonal Antibody 45-J Test
  • Monoclonal Antibody Technology
  • mRNA Technology
  • Multiple Sclerosis
  • Multiple Sclerosis - Relasping
  • Multiple Sclerosis Therapy - Copaxone
  • Naked DNA Technology
  • Nanocrystalline Particles
  • NASA Technology
  • Nasal Decongestant
  • Nasal Vitamin B-12 Therapy
  • Natural Cell Signaling Phenomenon
  • Nerve Repair
  • Nervous System Therapeutics
  • NeuroCell Joint Venture
  • Neurodegenerative and Psychiatric Diseases Therapy
  • Neurological
  • Neurology - Menkes disease
  • Neurotrophic Factor Commercialization
  • Nicotine Addiction Treatment
  • Nifedipine Crystals
  • Novasome Lipid Vesicles Encapsulation Technology
  • Nuclear Matrix Protein Technology
  • Nucleic Acid
  • Nureologogical Disorders Anti-agitation Drug
  • Nutrition - Salt Alternative
  • Obesity
  • Obesity Therapy
  • Opthalmic
  • Oral Contraceptive
  • Osteoarthritis Treatment for Animals
  • Osteoporosis Compound 1-apiha-hydroxyvitamin D2
  • Oxygenation
  • Pain Management
  • Parkinson's Disease
  • PEG Enhanced L-asparaginase
  • Pegylated Reagent
  • Personal Care
  • Pet Medication
  • Photodynamic Therapy
  • Platinate HPMA Copolymer
  • Pneumocystis Carinii Pneumonia
  • Poly (ADP Ribose) Polymerase Diagnostic Assay
  • Polymerase Chain Reaction Technology
  • Pre-eclampsia/Toxemia Diagnosis and Therapy
  • Primary Biliary Cholangitis
  • Pro-Apolipoprotein A-I and Lipid Complexes
  • Progesterone Gel
  • Protein Secretion Technology
  • Proteomics Technology
  • Psychiatric & Psychotic Therapy
  • Psychotherapeutic Drugs
  • Pulmonary Disease
  • Radynilel Hypoxic Tumor Cell Radiosensitizer
  • Rapid Diagnostic Test
  • RAS Human Protein/Rational Drug Design
  • Recombinant Human Erythropoietin- Procrit
  • Recombinant Human Inerlukin-twelve (rhIL-1 2)
  • Recombinant Technology
  • Respiratory Therapy
  • Retinoids
  • Rhenium Radiotherapy and Monoclonal Antibodies
  • Ribozymes
  • Rickets - x-linked hypophosphatemia treatment
  • RNAi Interference Technology
  • RNAi Interference Therapies
  • Sarafem
  • Schizophrenia
  • Schizophrenia and Bipolar Treatment
  • Septic Shock Treatment - Human Thymosin beta 4 (T?4), a 43-amino acid peptide
  • Sexual Dysfunction Therapy
  • Skin Disorder
  • Skin Technology - Polyactive Polymer Biomaterial
  • Sleep Therapy
  • Spirulina
  • Spleen Tyrosine Kinase (Syk) Inhibitor
  • Stem Cell
  • Stem-loop Vector Technology
  • Stromal Derived Factor 1 (SDF-1) Peptide Agonists and Antagonists
  • Sugar Substitute
  • TamifluT
  • TelavancinT - Antibotic
  • Testosterone Replacement
  • TGF-beta
  • Thalidomide
  • Thalidomide Analogs
  • Thymidine Kinase Isoenzyme Diagnostics
  • Tissue Malignancy Treatments
  • Topical Adminstration Technology
  • Transdermal Estrogen Patch
  • Tropical Plants
  • Ultrasound Contrast Agent
  • Vaccine Research
  • Vaccines, gene-based
  • Virus Prevention and Treatment - Coronavirus
  • Virus Vaccines
  • Wart Removal Products
  • Water-Jel Sterile Burn Dressings
  • Yeast-based Screening Technology

For more information about this report visit https://www.researchandmarkets.com/r/7fm5y6

Media Contact:

Research and Markets 
Laura Wood, Senior Manager 
[email protected] 

For E.S.T Office Hours Call +1-917-300-0470 
For U.S./CAN Toll Free Call +1-800-526-8630 
For GMT Office Hours Call +353-1-416-8900 

U.S. Fax: 646-607-1907 
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.